Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
Early Parkinson's Disease Monotherapy With CVN424
NCT06006247 · View on ClinicalTrials.gov ↗
Study Summary
This is a multicenter, 12-week, placebo-controlled clinical trial of CVN424 150 milligrams (mg) tablets in early, untreated Parkinson's Disease (PD). Participants will be randomized in a 1:1 ratio to CVN424 150 mg or placebo at the Baseline Visit. The purpose of this study is to measure effect on motor features with CVN424 tablets compared to placebo in early, untreated PD and to evaluate the potential of CVN424 to improve motor and non-motor functions in participants with early PD who are not taking dopaminergic or anti-PD therapies.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG CVN424 150 mg
Study Locations (20)
Florida
- Parkinson's Disease and Movement Disorders Center of Boca Raton — Boca Raton
- SFM Clinical Research, LLC — Boca Raton
- N1 Research LLC — Orlando
- Parkinson's Disease Treatment Center of SWFL — Port Charlotte
- University of South Florida Parkinson's Disease and Movement Disorders Center — Tampa
Arizona
- Barrow Neurological Institute — Phoenix
- St Joseph's Hospital and Medical Center — Phoenix
- Muhammad Ali Parkinson Center — Phoenix
- Movement Disorders Center of Arizona, LLC — Scottsdale
Michigan
- University of Michigan Hospital / Michigan Clinical Research Unit (MCRU) Cardiovascular Center — Ann Arbor
- University of Michigan Department of Neurology — Ann Arbor
- Quest Research Institute — Farmington Hills
Kentucky
- University of Kentucky, Dept of Neurology Kentucky Neuroscience Institute Research — Lexington
- University of Kentucky, Center for Clinical and Translational Sciences — Lexington
Alabama
- University of Alabama at Birmingham — Birmingham
California
- Parkinson's Research Centers of America - Palo Alto — Palo Alto
Colorado
- CenExel Rocky Mountain Clinical Research — Englewood
Georgia
- Augusta University — Augusta
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 64 participants |
| Start Date | 2023-09-11 |
| Est. Completion | 2025-02-13 |
| Phase | Phase 2 |
Interested in This Trial?
Always speak with your doctor before enrolling in a clinical trial.
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06006247
The ClinicalTrials.gov registry entry for NCT06006247 describes a study currently listed as completed. It is categorized as Phase 2, which is the standard way researchers label where a study sits along the investigational pathway from early safety work through later efficacy and post-marketing evaluation. The registered enrollment target is 64 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Cerevance Beta, which has 2 total studies on file at ClinicalTrials.gov, and sponsors are the parties responsible for study design, oversight, and regulatory filings.
The record links to 1 condition, with Parkinson's Disease appearing as the primary indexed condition, and to 2 interventions — of which Placebo is the first listed. Interventions can include drugs, devices, procedures, behavioral programs, or observational arms, and each is tracked as a separate registry field so that downstream queries can filter accurately. When a trial lists multiple interventions, it usually reflects a multi-arm design or a comparison protocol rather than a single treatment being tested in isolation. The brief summary published in the registry is the clearest source of protocol intent and should be read before drawing conclusions from any sidebar tags.
Geographic footprint matters for practical reasons: NCT06006247 reports 20 study locations spanning 10 distinct geographic areas — top geographies include Florida, Arizona, Michigan. A larger site network tends to correlate with broader recruitment capacity, but it does not imply anything about study quality, and site-level enrollment status can diverge from the overall registry status shown above. Every data point on this page comes from the public ClinicalTrials.gov dataset and is reproduced here for reference only; it is not a medical recommendation, an endorsement of the sponsor, or an invitation to enroll. Verify current status, eligibility criteria, and contact details directly at ClinicalTrials.gov, and discuss any participation decision with your own healthcare provider.
Frequently Asked Questions
What is clinical trial NCT06006247 about?
NCT06006247 is a clinical study titled "Early Parkinson's Disease Monotherapy With CVN424". This is a multicenter, 12-week, placebo-controlled clinical trial of CVN424 150 milligrams (mg) tablets in early, untreated Parkinson's Disease (PD). Participants will be randomized in a 1:1 ratio to CVN424 150 mg or placebo at the Baseline Visit. The purpose of this study is to measure effect on mo...
What is the current status of trial NCT06006247?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 64 participants. The study started on 2023-09-11. Estimated completion is 2025-02-13.
What conditions does trial NCT06006247 study?
This clinical trial studies the following conditions: Parkinson's Disease. These conditions were identified from the trial registry and reflect the primary focus areas of the research.
What interventions are being tested in trial NCT06006247?
The interventions under investigation include: Placebo (DRUG), CVN424 150 mg (DRUG). Each intervention is being evaluated for safety and efficacy as part of this clinical study.
Who is sponsoring clinical trial NCT06006247?
This trial is sponsored by Cerevance Beta, which has 2 total clinical trials registered on ClinicalTrials.gov. The sponsor is responsible for the study's design, funding, and regulatory compliance.
Where is trial NCT06006247 being conducted?
This trial has 20 study locations across Alabama, Arizona, California, Colorado, Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How Clinical Trials Work
Understand phases 1-4, trial design, randomization, and the informed consent process.
Patient Rights in Clinical Trials
Your rights as a participant: consent, withdrawal, privacy, and who to contact.
Finding the Right Clinical Trial
A practical guide to searching trials, understanding eligibility, and evaluating options.
All Guides
Browse our complete library of clinical trial educational resources.
Read our methodology — how this data is sourced, computed, and verified.